A European defence startup is making drone submarines that can lurk underwater for 3 months at a time

German military tech startup Helsing said it is readying a fleet of undersea drones amid intensifying threats to subsea cables, and said they'd be ready to deploy in around a year.
The uncrewed submarine, the SG-1 Fathom, would be able to patrol and stay underwater for up to three months at a time, it said.
In a statement Tuesday, the company said that its AI Lura software detects subsea threats and can identify ship and submarine models from their underwater sound patterns.
It claimed the software operates 40x faster than human operators, and is 10x quieter than other models, meaning it's better able to evade detection.
"We must harness new technologies to keep pace with the threats against our critical infrastructure, national waters, and way of life," said Gundbert Scherf, cofounder and co-CEO of Helsing.
Hundreds of the drones could be deployed at the same time, controlled by a single operator, the company said, monitoring undersea regions for threats and relaying live data.
Bryan Clark, a senior fellow at the Hudson Institute in Washington, DC, told BI that underwater drones such as the ones being developed by Helsing "would be effective at monitoring underwater infrastructure."
He added that each drone's detection range is "quite short," but that the system is designed to manage dozens or even hundreds at a time.
Clark also said that underwater drones could be vulnerable to electronic jamming, which could impact their navigation systems and cause them to get "lost."
Helsing's announcement comes amid intensifying threats to networks of subsea cables crucial for carrying internet data.
European officials blamed Russia for a series of subsea cable severances in the Baltic late last year and in January, which some said was part of the Kremlin's "hybrid warfare" campaign.
In September, Business Insider reported that a specialist Russian submarine sabotage unit had been surveilling subsea cables.
NATO has formed its own special unit to better defend critical underwater infrastructure, and has also said it's developing new satellite technology so that data can be rerouted in the event of a massive disruption.
European militaries are also testing and deploying sea drones as part of their bid to increase undersea monitoring and shore up defenses.
The UK's military, as part of its Project Cabot, is testing new drone and AI technology to monitor underwater infrastructure, and is working with Helsing on the project, The Times of London reported Tuesday.
Helsing has already produced AI systems and aerial drone systems for European militaries, and was valued at $5.4 billion during a funding round last year.
It said it had developed the sea drones following interest from several navies, and had tested them at a naval base in the south of England.
"Deploying AI to the edge of underwater constellations will illuminate the oceans and deter our adversaries, for a strong Europe," Helsing's Scherf said.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

Women are getting wealthier — and they don't invest the same way as men

Women are becoming richer, and they're changing the face of wealth. According to a report by McKinsey published last month, women control about a third of all retail financial assets in the US and the European Union. By 2030, that proportion is expected to rise to between 40% to 45%, wrote Cristina Catania, global co-convener and European lead for the risk and resilience practice, and Jill Zucker, senior partner and co-leader of McKinsey's global growth transformation service line. The report is based on a survey of about 13,000 American and European investors, nearly half of whom were female financial decision makers. It found that between 2018 and 2023, global wealth rose by 43%, but jumped by 51% for women. Women's expanding control of assets is being driven by a combination of factors, including a continuing decline in marriage rates, the ongoing boost in women's average earnings, demographic trends like longer life expectancies, and a broad shift in attitudes about women managing their own finances. Risk doesn't equal reward As women become wealthier through investing, it's becoming clearer that they don't approach it the same way as men. "Women are much more risk-aware," Anna-Sophie Hartvigsen, cofounder of financial education and investment platform Female Invest, told Business Insider. "I would like to call it much more realistic in their own ability to invest." She said women are less likely than men to invest emotionally. "On average, men trade a lot more often than women because they believe they can beat the market or they read something in the news, and they get pumped up or afraid, and then they invest based on that," Hartvigsen said. Female investors, in her view, tend to be more calm, more realistic, and better at assessing risk. However, Katie Geery, an advisor at Rise Private Wealth Management, says being more cautious can also hold women back by leading them to miss out on opportunities to build wealth. "It is important to work with a trusted financial advisor who understands your risk tolerance and can walk you through making well-educated investment decisions based on your long-term goals," she told BI. Returns aren't everything The aims of investing also sometimes differ between men and women. "Women prefer to invest toward achieving specific goals rather than chasing the highest returns," said Avanti Shetye, financial planner at Wealthwyzr. Geery said female investors tend to be more focused on philanthropy and gifting. They often consider their values when buying stock and want their purchases to help make a better impact on the world. "Women often seek financial advisors who are empathetic and take the time to get to know them on a more personal level to gain a deeper understanding of their goals and values," she said. On Female Invest, Hartvigsen said the principles its members care about the most include climate, especially a firm's carbon footprint, and diversity in leadership, in terms of a board having a good gender balance. Start investing early For Shetye, it's important to start investing early. "Women tend to be primary caregivers for children or aging parents and often take unpaid time off," she said. "Not only that, women statistically live longer than men, which implies that women would need to invest as much as they can as early as possible so that their portfolios last them through retirement." Hartvigsen said long-term financial planning is vital: "When you do that, it doesn't matter what happens today." Both agree that this plan should be grounded in expert advice. "Working with a financial planner whose planning process is rooted in financial education can help provide comfort and security to stay consistent even in the roughest of markets," Shetye said. But she also believes that practice is more important than perfection. "You are never going to know everything there is to know about investing," Shetye said. "The key is consistency, and time will do the heavy lifting." Hartvigsen advises her clients to invest monthly on the same day and to diversify their investments. "If you do that, historically, it has been near impossible not to make money in the long run."

The Hill

an hour ago

• The Hill

Food and Drug Administration staff cuts may hinder US biomedical innovation

President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.

Business Insider

7 hours ago

• Business Insider

Amazon CEO Andy Jassy came clean about AI's impact on white-collar jobs. That might be a good thing.

Welcome back to our Sunday edition, where we round up some of our top stories and take you inside our newsroom. A 35-year-old is done saving for retirement with more than $1.125 million across his investments. He explained his unorthodox path to getting there, which included one very risky trade. On the agenda today: Gen X is already living millennials' real-estate nightmare. Two status symbol credit cards are getting upgrades this year. BI visited three Target stores across the US to understand why it's struggling. Steve Schwarzman has a message for Blackstone's newest intern class. But first: Rip the Band-Aid off. If this was forwarded to you, sign up here. Download Business Insider's app here. This week's dispatch REUTERS/Brendan McDermid AI acknowledgment One way to think about Amazon CEO Andy Jassy's AI warning: It's better to hear it sooner than later. In a note to staffers last week that rocked the corporate world, Jassy said AI "should change the way our work is done," and he expects the technology will eventually lead to fewer white-collar jobs at Amazon. He isn't the first CEO to warn about AI's impact on jobs, but he is the most high-profile leader to do so. (Amazon, with about 1.5 million workers, is the second-largest private employer in the US.) As my BI colleague Tim Paradis reported, there's an upside to hearing Jassy's forthrightness about AI. "If I were an employee, I would be very frustrated with my leader saying, 'No, we're still not sure if this is going to have an impact,'" Christopher Myers, the faculty director of the Center for Innovative Leadership at the Johns Hopkins Carey Business School, told Paradis. He said it's better for executives to acknowledge that AI "almost certainly" will change roles and perhaps impact entire org charts. Jassy joins a list of CEOs who have recently offered AI warnings, including companies tied to the tech's success like OpenAI's Sam Altman, Anthropic's Dario Amodei, and Nvidia's Jensen Huang. To be sure, a former Amazon developer told BI that Jassy's memo didn't surprise him. He doesn't think engineers should worry about their jobs, as he thought the memo was more about showing shareholders that Amazon was serious about the technology. Overall, workers have mixed feelings about these AI warnings. Elaine Ryan, a psychologist with two decades of experience, told BI that she thinks people who have anxiety over AI feel disoriented by the sheer scale of the technology. They don't just worry about losing their jobs but also about losing relevance or their sense of identity. Amid the warnings and anxiety, there is plenty of advice about what workers can do in the current environment. Duolingo CEO Luis von Ahn has said it's important to respond to AI with curiosity, not fear. "The sooner we learn how to use it and use it responsibly, the better off we will be in the long run," he said. Jassy said Amazon employees who show a willingness to embrace AI "will be well-positioned to have high impact and help us reinvent the company." And Ryan, the psychologist, said that while AI might be new, the way we respond to the uncertainty surrounding it isn't. "The goal isn't to compete with the machine. It's to reclaim the human part— the experience, the depth, the emotional intelligence — that still matters more than we think," she said. The plight of the sandwich generation Many Gen Xers are in a financial bind. They're managing the real-estate assets of their aging parents while also helping pay rent for their adult children — two cohorts that, for different reasons, can't quite support themselves on their own. That pressure has left some Gen Xers emotionally exhausted and wondering if they'll even be able to afford retirement. Still, they're not giving up. Travelers and foodies, rejoice! New perks and updates are coming to two of the most popular credit cards. American Express said updates are coming to its Platinum Card later this year. JPMorgan Chase also announced a revamp to its Sapphire Reserve Card. Cardholders will see new spending perks in categories like travel, dining, and lifestyle. But it's getting a price hike. Here's what $795 a year will get you. Target's trying times In recent years, Target has fallen behind. The retailer has struggled to grow its sales as competitors Costco and Walmart have posted strong gains. Analysts and some customers on social media say the general state of Target's stores is a key issue. BI visited three Target locations across the US — Madison, Wisconsin, Ventura, California, and Washington, DC — to find out why the retailer is struggling. Each store offered a different experience. Here's what BI saw. Wait, is Walmart cool again? Dear Blackstone interns … Blackstone CEO Steve Schwarzman greeted the firm's 170 summer interns with some choice advice: If you want to succeed in private equity, learn to go with the flow. It's an industry where "nothing ever stays the same," Schwarzman said, according to a Blackstone spokesperson. "So if you have a mind and a curiosity that fits with that kind of world — constant new things, new learning — then you've come to the right place." Change is the constant. This week's quote: "The index is going nowhere." — Billionaire investor Leon Cooperman gave BI his outlook on the stock market. More of this week's top reads: AI and sports were hot topics at the ad industry's Cannes Lions bash. Just don't mention "brand safety." Ambitious Gen Zers are struggling to get jobs despite having college degrees. The Big Stay is finally paying off: Quitting to job-switch is worse for wage growth than sticking it out. Private equity took Jamie Dimon's warnings to heart. Here's why. Job search going nowhere? Try this. Will AI kill TV or make it smarter? Media execs share five key ways the industry is transforming. The 25 most innovative CMOs of 2025. An ex-Harvard professor says his AI could prevent the next world war. Critics say it could start one. "Copilot" this, "Copilot" that. A watchdog wants Microsoft to change its confusing AI advertising. Get ready for WhatsApp ads.